The value of information and optimal clinical trial design.
about
When Quality Beats Quantity: Decision Theory, Drug Discovery, and the Reproducibility CrisisCurrent sample size conventions: flaws, harms, and alternativesGoal-setting intervention in patients with active asthma: protocol for a pilot cluster-randomised controlled trial.Statistical analysis of cost-effectiveness data from randomized clinical trials.Is a comparative clinical trial for breast cancer tumor markers to monitor disease recurrence warranted? A value of information analysisUsing value-of-information methods when the disease is rare and the treatment is expensive--the example of hemophilia A.A cost-effectiveness analysis of a preventive exercise program for patients with advanced head and neck cancer treated with concomitant chemo-radiotherapy.Economic return from the Women's Health Initiative estrogen plus progestin clinical trial: a modeling study.When to wait for more evidence? Real options analysis in proton therapy.Non-invasive versus invasive management in patients with prior coronary artery bypass surgery with a non-ST segment elevation acute coronary syndrome: study design of the pilot randomised controlled trial and registry (CABG-ACS)Decision-theoretic designs for small trials and pilot studies: A reviewPrimary outcomes for resuscitation science studies: a consensus statement from the American Heart Association.Computing Expected Value of Partial Sample Information from Probabilistic Sensitivity Analysis Using Linear Regression MetamodelingHow Have Cancer Clinical Trial Eligibility Criteria Evolved Over Time?Decision analysis for resource allocation in health care.Are value of information methods ready for prime time? An application to alternative treatment strategies for NSTEMI patients.Simple, defensible sample sizes based on cost efficiency.A feasibility study incorporating a pilot randomised controlled trial of oral feeding plus pre-treatment gastrostomy tube versus oral feeding plus as-needed nasogastric tube feeding in patients undergoing chemoradiation for head and neck cancer (TUBSample size determination for cost-effectiveness trials.A systematic and critical review of the evolving methods and applications of value of information in academia and practice.New insights into the evaluation of randomized controlled trials for rare diseases over a long-term research horizon: a simulation study.Development and Evaluation of an Approach to Using Value of Information Analyses for Real-Time Prioritization Decisions Within SWOG, a Large Cancer Clinical Trials Cooperative Group.Analytic approaches for research priority-setting: issues, challenges and the way forward.A Practical Application of Value of Information and Prospective Payback of Research to Prioritize Evaluative Research.A practical guide to value of information analysis.Value of information analysis optimizing future trial design from a pilot study on catheter securement devices.Value of information methods for assessing a new diagnostic test.A mathematical model for maximizing the value of phase 3 drug development portfolios incorporating budget constraints and risk.Dangerous omissions: the consequences of ignoring decision uncertainty.The Burden of the "False-Negatives" in Clinical Development: Analyses of Current and Alternative Scenarios and Corrective Measures.Clinical decision making and the expected value of information.Paying for personalized care: cancer biomarkers and comparative effectiveness.Economic evaluation of factorial randomised controlled trials: challenges, methods and recommendations.Breaking free of sample size dogma to perform innovative translational research.Accounting for between-study variation in incremental net benefit in value of information methodology.Addressing adoption and research design decisions simultaneously: the role of value of sample information analysis.Optimal sample size determinations from an industry perspective based on the expected value of information.Dimensions of design space: a decision-theoretic approach to optimal research design.Valuing Trial Designs from a Pharmaceutical Perspective Using Value-Based Pricing.An optimization approach to calculating sample sizes with binary responses.
P2860
Q24288687-EFF5EAE9-3529-442A-AA4D-B0B772A74552Q24288939-B66CA846-4BF8-4AFA-8FB6-9B6B6D05FD48Q30558301-125B8D0B-9DEE-49D3-98E7-1661C44B7885Q33596439-056C0FFA-A9B9-40B9-B031-1CCADE337032Q33599906-98FAC07D-CBBA-4505-A4BE-40F15BCCE903Q34011908-A083B01D-67D8-4166-86D7-3E4E0A488E57Q34066375-E95AE02C-40D9-4116-8EBB-8357E8666FEDQ34147730-79F923CE-4651-4ECD-A01F-ABAAB3BEFAD7Q35642383-1C0E0356-A107-47FB-BE21-3C82C1859C6EQ36819302-BADACC79-B58A-4E8C-A272-B09A999EAA68Q36925422-3E66E3FE-DDE4-421B-8179-66A3D100D2C0Q37035544-F4E471F8-94C8-480E-8436-6DDD0243DACFQ37163118-74C764D0-1237-4B72-B6C1-42BD51C64DE4Q37211235-15A603A2-D6E7-46E4-89C3-2E6148777A06Q37275135-78A2BB08-B098-4F1B-81CA-9225651EC693Q37355389-BAE03DE3-C3FB-4AE7-8238-C99775903287Q37403854-225264DC-3296-4508-992E-2AC9121ED916Q37498291-7EEBC76B-FC67-41E2-AC5F-1A955655CCA6Q37944317-21556B40-1839-4137-AD8D-337D059B9466Q38074914-4B379791-20AC-4B42-BC09-AF4D7F5B82F0Q38888445-C29AA139-0470-494C-A670-B3DCED25FBDCQ38890570-16F1E44F-E80B-4734-8DC5-5709C7474BB3Q38960831-CE749C16-1DD2-4A28-8947-C1908FBFDDFEQ38981381-D7769D82-3D6E-4BB3-B186-4A60F25AF145Q39109596-C1388EFC-1D3B-4AC4-A2C6-BCFB9CB07C11Q39149842-E95A71AB-75A0-4586-A74A-8C91759008E2Q39276772-3FD16B63-BDD1-457B-8FE7-46F6BB4D9FFFQ39489357-0AE4C5B1-F0EB-46D9-9BAE-64A308D853B9Q39907951-B5A6E425-EA45-4D51-8DFD-E7B4821F4302Q40135662-141BAD9A-7382-4664-A2A9-2240B8E571DAQ40181014-74371CB5-2B93-40EA-9D49-AE2FC55CCD96Q41376969-A7190A58-830B-4200-A102-1D9252279687Q41990253-CD128B62-163F-4ECB-9E6B-098C424B4ED5Q42117164-2DED3307-201C-4045-A147-976E51209EC5Q44458792-BA08EB45-BB35-402B-B6EB-9B799EAF2346Q44679857-58F5BD92-8D33-492E-9523-D4A55CF8231FQ45227163-F0E16F49-5609-4BB3-9C55-3310913D073AQ45928290-062A7D80-8DEA-42D9-9A06-30939DD22DD8Q45930178-04F82BD2-5F33-494E-A7CB-3762B9D50896Q46353455-7D62EFDC-FF44-49FB-9529-F0DC14254F32
P2860
The value of information and optimal clinical trial design.
description
2005 nî lūn-bûn
@nan
2005年の論文
@ja
2005年学术文章
@wuu
2005年学术文章
@zh
2005年学术文章
@zh-cn
2005年学术文章
@zh-hans
2005年学术文章
@zh-my
2005年学术文章
@zh-sg
2005年學術文章
@yue
2005年學術文章
@zh-hant
name
The value of information and optimal clinical trial design.
@en
The value of information and optimal clinical trial design.
@nl
type
label
The value of information and optimal clinical trial design.
@en
The value of information and optimal clinical trial design.
@nl
prefLabel
The value of information and optimal clinical trial design.
@en
The value of information and optimal clinical trial design.
@nl
P356
P1476
The value of information and optimal clinical trial design.
@en
P2093
Andrew R Willan
Eleanor M Pinto
P304
P356
10.1002/SIM.2069
P407
P577
2005-06-01T00:00:00Z